When regulatory strategy starts after prototyping, things don’t just slow down—they break. And once they break, they are expensive to fix.

Medical device development is not linear. FDA expectations are woven into design, testing, and evidence generation. When those expectations are ignored early, downstream failures stack up fast.

What Actually Goes Wrong (and Why It Hurts)
1. Studies That FDA Will Not Accept

Late regulatory involvement often means studies are designed without FDA logic in mind. Common problems include:

Wrong test models

Missing controls

Non-relevant endpoints

Poor linkage to intended use

The result? Data that looks impressive internally but is regulatorily unusable.

Impact:

Repeating bench or animal studies can cost $250,000–$1M+

Adds 6–12 months to development timelines

FDA does not approve effort. They approve evidence.

2. Wrong Endpoints, Wrong Conclusions

If intended use and risk classification were not nailed down early, teams often measure the wrong things:

Performance endpoints that don’t support safety claims

Bench tests that don’t map to clinical risk

Human factors studies done on the wrong user population

When endpoints don’t align with FDA expectations, even “positive” results can be meaningless.

Impact:

Entire studies may need to be redesigned

Lost investor confidence when timelines slip

Delays to first-in-human or submission milestones

3. Data That Cannot Be Traced or Defended

FDA expects traceability:

Risks → design inputs → verification → validation

Evidence tied directly to hazard mitigation

When regulatory planning is late, documentation gaps appear:

No clear rationale for why tests were selected

Weak linkage between risks and evidence

Incomplete design history files

This turns FDA review into a prolonged back-and-forth instead of a clean submission.

Impact:

Multiple FDA information requests

Longer review cycles

Higher likelihood of refusal-to-accept (RTA)

4. Forced Regulatory Pathway Changes

This is the most painful failure.

Late discovery that:

Your device is higher risk than assumed

A 510(k) is not viable

De Novo or PMA is required instead

At this point, the problem is not regulatory—it’s strategic.

Impact:

12–24 months of additional development

Millions in unplanned spend

Potential need to redesign the device entirely

This is how promising startups quietly die.

The Cost of Starting Too Late (Reality Check)

Across the industry, late regulatory strategy commonly results in:

30–50% cost overruns

1–2 years of avoidable delays

Repeated testing with no added value

Lost first-mover advantage

And no—“we’ll fix it in regulatory later” has never saved a program.

Where Kandih Comes In

This is exactly what Kandih Group exists to prevent.

Kandih works upstream—before rework is needed—to:

Align development plans with U.S. Food and Drug Administration expectations from the start

Define the right regulatory pathway early

Ensure studies are designed with FDA-acceptable endpoints

Build evidence strategies that are defensible, traceable, and submission-ready

Eliminate redundant testing and wasted spend

Instead of cleaning up mistakes, we help you avoid making them.

Bottom Line

Late regulatory strategy doesn’t just slow you down.
It creates invalid data, forces redesigns, and drains capital.

The fastest path to market is not skipping regulatory strategy—it’s aligning with FDA logic early and building once.

That’s how Kandih keeps development efficient, credible, and fundable.

References

FDA – Design Controls for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-controls-medical-devices

FDA – Refuse to Accept Policy for 510(k)s
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/refuse-accept-policy-510ks

FDA – Benefit-Risk Factors to Consider for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-when-making-benefit-risk-determinations-medical-device

FDA – ISO 14971: Risk Management for Medical Devices
https://www.fda.gov/medical-devices/standards-and-conformity-assessment-program/recognized-consensus-standards